卡博替尼与凡德他尼治疗晚期甲状腺髓样癌的真实世界疗效与安全性
该回顾性分析纳入1990至2018年间四家德国三级医疗中心的48例晚期甲状腺髓样癌患者,评估凡德他尼与卡博替尼在临床试验外的疗效与治疗中出现的不良事件。凡德他尼组中位无进展生存期17个月,卡博替尼组4个月;中位总生存期分别为53个月和24个月。作者认为卡博替尼组预后较差可能与其作为凡德他尼治疗失败后的二线治疗有关。
要点
- 凡德他尼组中位无进展生存期17个月,卡博替尼组4个月。
- 凡德他尼组中位总生存期53个月,卡博替尼组24个月。
- 凡德他尼组部分缓解12例(26%),卡博替尼组5例(22%)。
核心结论
- 凡德他尼和卡博替尼是多数甲状腺髓样癌患者的有效治疗选择。
- 作者推测回顾性分析中卡博替尼治疗患者预后较差最可能是因其作为凡德他尼治疗失败后的二线治疗,但两种药物疗效不同也有可能。
研究设计与样本
- 回顾性分析,纳入1990年至2018年间在四家德国三级医疗中心诊断的48例甲状腺髓样癌患者,评估临床试验外凡德他尼和卡博替尼的临床特征、治疗方案、疗效及治疗中出现的不良事件。
- 采用Kaplan-Meier法估计无进展生存期和总生存期概率,采用log-rank检验进行比较。
主要发现
- 诊断时中位年龄46岁(范围15-80岁);已知胚系RET突变者6例(13%)。
- 启动TKI前32例(67%)患者显示疾病进展。
- 47例(98%)患者接受凡德他尼治疗,23例(48%)患者接受卡博替尼治疗;凡德他尼作为一线治疗41例(85%),卡博替尼作为一线治疗7例(15%)。
- 凡德他尼组最佳疗效为部分缓解12例(26%),卡博替尼组5例(22%);凡德他尼组疾病稳定≥24周16例(34%),卡博替尼组3例(13%)。
- 凡德他尼组中位无进展生存期17个月(95%CI 9.3-24.6个月),卡博替尼组4个月(95%CI 3.1-4.9个月)。
关键数值与推荐
- 凡德他尼组6个月和12个月生存率分别为98%和86%,卡博替尼组分别为78%和70%。
- 凡德他尼组中位总生存期53个月(95%CI 43.7-62.3个月),卡博替尼组24个月(95%CI 5.9-42.1个月)。
- 凡德他尼治疗患者中,启动TKI时年龄≤60岁及发生≥5种治疗中出现的不良事件者无进展生存期和总生存期显著更长;无骨转移者无进展生存期更长。
- 卡博替尼治疗患者中,发生治疗中出现的不良事件者及年龄≤60岁者无进展生存期显著更长;发生治疗中出现的不良事件者及发生≥5种治疗中出现的不良事件者总生存期显著更长。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Management of patients with advanced medullary thyroid cancer (MTC) remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) vandetanib and cabozantinib have been approved for the treatment of progressive MTC based on prolonged progression-free survival (PFS) in phase 3 clinical trials. Patients and Methods: To evaluate clinical characteristics, treatment regimens, efficacy, and treatment emergent adverse events (TEAEs) of vandetanib and cabozantinib in MTC patients outside clinical trials at four German tertiary care centers. Forty-eight patients diagnosed between 1990 and 2018 were included. PFS and overall survival (OS) probabilities were estimated using the Kaplan-Meier method and compared by log-rank test. Results: The median age at diagnosis was 46 years (15-80 years); a germ line RET (rearranged during transfection) mutation was known in 6 (13%) patients. Thirty-two (67%) patients showed progressive disease before TKI initiation. Forty-seven (98%) patients were treated with vandetanib and 23 (48%) patients with cabozantinib. Vandetanib was first-line treatment in 41 (85%) patients and cabozantinib in 7 (15%) patients. Partial response was the best response in 12 (26%) patients treated with vandetanib and in 5 (22%) patients treated with cabozantinib. Sixteen (34%) patients treated with vandetanib and 3 (13%) patients treated with cabozantinib had stable disease ≥24 weeks. The median PFS for vandetanib and cabozantinib was 17 months [95% confidence interval, CI, 9.3-24.6 months] and 4 months [CI 3.1-4.9 months], respectively. The 6- and 12-month survival rates were 98% and 86% for vandetanib and 78% and 70% for cabozantinib, respectively. The median OS for vandetanib and cabozantinib was 53 months [CI 43.7-62.3 months] and 24 months [CI 5.9-42.1 months], respectively. In vandetanib-treated patients, the PFS and OS were significantly longer in patients aged ≤60 years at TKI initiation and in patients with ≥5 TEAEs. Additionally, the PFS was longer in the absence of bone metastases. In cabozantinib-treated patients, the PFS was significantly longer in patients experiencing TEAEs and in patients aged ≤60 years, and the OS was significantly longer in patients who had TEAEs and in patients with ≥5 TEAEs. Conclusions: Vandetanib and cabozantinib are effective treatment options in the majority of MTC patients. We hypothesize that the poorer prognosis of cabozantinib-treated patients in our retrospective analysis is most likely due to its use as second-line treatment after treatment failure on vandetanib. However, different degrees of efficacy of the two drugs are possible.
引用
- Koehler VF, Adam P, Frank-Raue K, et al. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Thyroid. 2020. PMID: 32781914. doi:10.1089/thy.2020.0206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。